AbbVie Inc.
AbbVie Reports Q2 2025 Financial Results with Adjusted EPS of $2.97
Summary
AbbVie Inc. reported second-quarter 2025 financial results with worldwide net revenues of $15.423 billion, an increase of 6.6% on a reported basis. The company reported a GAAP diluted EPS of $0.52 and an adjusted diluted EPS of $2.97, reflecting an unfavorable impact of $0.42 per share related to acquired IPR&D and milestones expense. AbbVie also raised its full-year 2025 adjusted diluted EPS guidance range from $11.67 - $11.87 to $11.88 - $12.08. Key product revenues showed mixed performance across portfolios, with notable growth in immunology and neuroscience, partially offset by declines in aesthetics and oncology. Recent developments include regulatory approvals and strategic investments.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement